TrialRMD open2022

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.

Huijing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.